Loading clinical trials...

ENROLLING_BY_INVITATIONEARLY_PHASE1

COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO

NCT06880042•Dr ayesha wahid

Summary

Patient of stable and limited vitiligo less than 20% BSA will be recruited And evaluation of efficacy and safety of narrowband UVB with topical tacrolimus vs narrowband UVB and calcipotriol will be assessed

Detailed Description

Evaulation of efficacy and safety of narrowband uvb and tacrolimus and NBUVB and calcipotriol in patient if stable vitiligo with body surface area less than 20% It will be assessed by VASI score and VIisual analogie scale

Eligibility

Age

15 - 70 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•\- Localized vitiligo Age 15 to 70years Body surface upto 20% Stable more than 3 months

Exclusion Criteria

•• Pregnant or lactating female patients.
•* Skin malignancy or any other malignant skin condition.
•* Photo induced or photo aggravated dermatosis like (SLE, photodermatitis, rosacea, psoriasis, pemphigus vulgaris) along with vitiligo.
•* Prior history of allergy to tacrolimus or calcipotriol.
•* Other form of treatment for vitiligo within at least 1 month.

Locations (1)

Lahore general.hospital

Lahore, Punjab Province, Pakistan

Key Dates

Start Date

May 1, 2025

Primary Completion Date

June 30, 2025

Completion Date

August 30, 2025

Last Updated

June 24, 2025

Enrollment

ESTIMATED participants

Conditions

Vitiligo - Macular DepigmentationTacrolimus

Interventions

Tacrolimus

DRUG

Calcipotriol

DRUG

Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma

NCT04056962

Tacrolimus, Kaposiform Hemangioendothelioma, Tufted Angioma

View study

UNKNOWN

Dosage of Tacrolimus Metabolites in Blood and Bile for Prediction of Its Side Effects in Liver Transplant Recipients

NCT05277792

Blood Concentration of Tacrolimus Metabolites

View study

UNKNOWNNA

Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 24, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions